Teva Pharma Lifts Annual Profit View on Strong Generic, Huntington's Disease Drug Sales
Reuters07-31
July 31 (Reuters) - Teva Pharmaceutical Industries raised its full-year profit forecast on Wednesday, banking on strength in its generic drug business and strong sales of its Huntington's disease drug.
Teva now expects its profit for the full year 2024 to be between $2.30 and $2.50 per share, compared with its previous expectation of $2.20-$2.50 per share.
The shares gained 0.9% in premarket trading Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.